'Big Science': Top funding for EU lung research project PULMOTENSION

February 10, 2006

Giessen. As of January 1, 2006, the European Union (EU) funds the Lung Research Project PULMOTENSION with an amount of Euro 11,4 Mio over a period of four years. The multidisciplinary approach integrates 31 institutions at top EU Centers in alliance with industrial partners in 12 European countries with the aim to combat and cure pulmonary hypertension (PH), a devastating lung disease. On February 9 and 10, 2006, the project leaders of PULMOTENSION held the constitutive meeting coordinated by Prof. Werner Seeger, Head of the University of Giessen Lung Center (UGLC) of the Justus-Liebig-University in Giessen, Germany.

Pulmonary hypertension (PH) describes a group of chronic, prolonged crippling and fatal vascular diseases. It is characterized by high blood pressure in the lung vessels leading to right heart failure. PH often affects young or middle-aged patients, who suffer from progressive loss of exercise capacity and dyspnoea. As a result, this serious lung disease represents a major burden on our healthcare systems.

With the formation of PULMOTENSION, European Top centers for scientific and technical competence in PH have taken a decisive step in tackling this large medical problem: Connected into a single project they aim to better understand and find a cure for this serious disease, because the large and complex tasks can only be addressed with the collected multidisciplinary competence and critical mass assembled. This pan-European "Big Science"- initiative allows the collaborating researchers to investigate basic science questions in terms of clinical applicability and provides a unique potential for scientific breakthroughs, technological advances and new treatments in the field of pulmonary hypertension.

"In this translational research concept the lung experts work "from bench to bedside" or "from the molecule to the patient": Over the next four years, we aim to uncover underlying molecular pathways of PH, identify distinct targets for anti-remodelling therapy, foster drug development based on these targets in alliance with industrial partners and exploitation facilities, and carefully test these new treatment options in preclinical and clinical trials", explains Werner Seeger, Head of the University of Giessen Lung Center (UGLC) of the Justus-Liebig-University of Giessen, Germany. "This is a huge but thrilling organizational challenge for all of us".

The combined expertise in PULMOTENSION extends from the initial discovery of gene mutations in PH to the establishment of new therapeutic regimen of PH. These include the discovery of BMPR2 mutations in PH, an effort led by Prof. Richard Trembath (King's College, London, United Kingdom) or the introduction of sildenafil (Viagra®) into the treatment of PH by a team of physicians led by Prof. Friedrich Grimminger (UGLC, Germany).
-end-
At the kick-off-meeting of PULMOTENSION in Giessen on February 9 and 10, 2006, the lung experts elected a central steering committee for this consortium and initiated research strategies, clinical trials and a European PH Tissue Bank and Registry.

For more information about PULMOTENSION and collaborating centers please visit: http://www.uglc.de/eu-six.html

University of Giessen Lung Center (UGLC)

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.